Monopar Therapeutics Inc. (NASDAQ: MNPR) presented new analyses from its Phase 3 FoCus clinical trial of ALXN1840 (tiomolibdate choline) at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA